INmune Bio, Inc. (INMB)
USD 4.57
(-8.33%)
USD 4.57
(-8.33%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.98 Million | -22.68 Million | -28.5 Million | -8.94 Million | -5.38 Million | -2.05 Million |
| Net Income | -30 Million | -27.29 Million | -30.34 Million | -12.09 Million | -7.67 Million | -12.44 Million |
| Depreciation & Amortization | 224 Thousand | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 7.36 Million | 7.14 Million | 4.79 Million | 3.11 Million | 4.09 Million | 10 Million |
| Change in working capital | 10.43 Million | -2.86 Million | -3.08 Million | 43.5 Thousand | -260.88 Thousand | 379.67 Thousand |
| Other non-cash items | 224 Thousand | 328 Thousand | 126 Thousand | 3.18 Million | -1.54 Million | 9.8 Million |
| Investing Cash Flow | - | - | -15 Million | - | - | - |
| Investments in PPE | - | - | -15 Million | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -15 Million | - | - | - |
| Financing Cash Flow | -4.22 Million | 729 Thousand | 96.35 Million | 23.89 Million | 12.2 Million | 900 Thousand |
| Debt repayment | -5 Million | - | -14.95 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -1.01 Million | - | - |
| Common Stock Issuance | 775 Thousand | 729 Thousand | 81.4 Million | 24.9 Million | 12.2 Million | 900 Thousand |
| Other Financing Activities | 775 Thousand | 729 Thousand | 81.4 Million | 24.9 Million | 12.2 Million | 900 Thousand |
| Accounts receivables | 6.01 Million | -2.95 Million | -3.7 Million | -1.15 Million | 2222.00 | -319.97 Thousand |
| Accounts payables | 2.72 Million | 1.4 Million | 2.26 Million | 1.07 Million | -131.67 Thousand | 514.04 Thousand |
| Inventory | - | 2.95 Million | 3.7 Million | 1.15 Million | -2222.00 | - |
| Other working capital | 1.69 Million | -4.26 Million | -5.34 Million | -1.03 Million | -129.2 Thousand | -134.37 Thousand |
| Cash at beginning of period | 52.15 Million | 74.81 Million | 21.96 Million | 6.99 Million | 186.2 Thousand | 1.37 Million |
| Cash at end of period | 35.84 Million | 52.15 Million | 74.81 Million | 21.96 Million | 6.99 Million | 186.2 Thousand |
| Capital Expenditure | - | - | -15 Million | - | - | - |
| Effect of forex changes on cash | -100 Thousand | -700 Thousand | -10 Thousand | 19.22 Thousand | -15.04 Thousand | -25.51 Thousand |
| Net cash flow / Change in cash | -16.3 Million | -22.65 Million | 52.84 Million | 14.97 Million | 6.8 Million | -1.18 Million |
| Free Cash Flow | -11.98 Million | -22.68 Million | -43.5 Million | -8.94 Million | -5.38 Million | -2.05 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.09 Million | -9.74 Million | -11.02 Million | -8.4 Million | -30 Million | -8.56 Million |
| Depreciation & Amortization | -24 Thousand | 24 Thousand | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.71 Million | 2.35 Million | 1.77 Million | 1.87 Million | 7.36 Million | 1.88 Million |
| Change in working capital | -1.22 Million | -514 Thousand | 1.73 Million | 3.08 Million | 10.43 Million | 2.35 Million |
| Other non-cash items | 4.63 Million | 3.02 Million | 647 Thousand | 45 Thousand | 224 Thousand | 54 Thousand |
| Investing Cash Flow | - | - | - | 2.55 Million | - | -2.55 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | 2.55 Million | - | - |
| Financing Cash Flow | 9.79 Million | 12.99 Million | -2.5 Million | -2.5 Million | -4.22 Million | -1.72 Million |
| Debt repayment | -5 Million | -2.5 Million | -2.5 Million | -2.5 Million | -5 Million | -2.5 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 12.29 Million | 15.49 Million | - | -775 Thousand | 775 Thousand | 775 Thousand |
| Other Financing Activities | 2.5 Million | 15.49 Million | -2.5 Million | 5.72 Million | 775 Thousand | -1.72 Million |
| Accounts receivables | 971 Thousand | -723 Thousand | -248 Thousand | -179 Thousand | 6.01 Million | -217 Thousand |
| Accounts payables | 1.2 Million | 71 Thousand | 1.41 Million | 4.18 Million | 2.72 Million | 1.36 Million |
| Inventory | - | - | - | 6.19 Million | - | 217 Thousand |
| Other working capital | -708 Thousand | 138 Thousand | 570 Thousand | -7.11 Million | 1.69 Million | 996 Thousand |
| Cash at beginning of period | 31.06 Million | 26 Million | 35.84 Million | 41.81 Million | 52.15 Million | 47.82 Million |
| Cash at end of period | 33.55 Million | 31.06 Million | 26 Million | 35.84 Million | 35.84 Million | 41.81 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -86 Thousand | -44 Thousand | 130 Thousand | -64 Thousand | -100 Thousand | -23 Thousand |
| Net cash flow / Change in cash | 2.48 Million | 5.06 Million | -9.84 Million | -5.96 Million | -16.3 Million | -6.01 Million |
| Free Cash Flow | -6.98 Million | -7.88 Million | -7.47 Million | -3.4 Million | -11.98 Million | -4.26 Million |
2686
HAWPF
603365
GGNDF
ELIMP
LFVN